Prostate CancerPhase 1NCT07344311
A Phase I Trial of A-CAR032 in Participants With mCRPC
A Phase 1 study testing dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection in people with Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, run by Shanghai AbelZeta Ltd. at 4 sites in China.
Trial summary
This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with mCRPC, who have previously progressed after ARPI treatment of prostate cancer (whether… Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
- What is being tested?
- dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 4 sitesChina
- Study dates
- 13 Jan 2026to 31 Jan 2042
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant must be 18 years or older at the time of signing the ICF. Type of Participant and Disease Characteristics
- Participants with:
- A histologically confirmed diagnosis of metastatic adenocarcinoma of the prostate without known neuroendocrine differentiation or small cell features.
- Castration-resistant prostate cancer as defined by disease progression despite castration by orchiectomy or ongoing luteinising hormone-releasing hormone analogue. Participants receiving medical castration therapy with gonadotropin-releasing hormone analogues should continue this treatment during the study.
- Measurable PSA≥1 ng/mL AND
- Evidence of progression within 6 months prior to screening
Show all 12Show fewer
- Participant has previously received an ARPI (ie, abiraterone, enzalutamide, apalutamide, darolutamide, rezvilutamide) whether before or in the metastatic castration-resistant setting, and in the judgment of the investigator, be ineligible for standard treatment.
- Minimum life expectancy of > 12 weeks prior to apheresis in the opinion of the investigator.
- Adequate organ and marrow function
- Consent and provision of tumour material to assess STEAP2 expression and other correlative biomarkers retrospectively with pre- and post-treatment biopsies.
- Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- The participant voluntarily participates in the study, and the individual or their legal guardian signs the ICF.
Who cannot join
- Known life-threatening allergies, hypersensitivity, or intolerance to the CAR-T product or its excipients, including dimethyl sulfoxide (DMSO).
- Contraindication to lymphodepleting agents, including fludarabine and/or cyclophosphamide.
- History of another primary malignancy except for:
- Malignancy treated with curative intent and with no known active disease within 3 years before the apheresis and of low potential risk for recurrence.
- Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease.
- Adequately treated carcinoma in situ without evidence of disease.
Show all 30Show fewer
- Participants with known brain metastases.
- History of splenectomy or organ transplantation.
- Prior treatment with:
- Any CAR-T therapy. OR
- Any therapy that is targeting STEAP2.
- Active or prior documented autoimmune or inflammatory disorders
- Cardiac arrhythmias which are symptomatic or require treatment unless controlled by pacemaker (judged by investigator); symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
- Active infection, including:
- HBV infection is defined as hepatitis B surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive and HBV DNA detectable.
- HCV infection is defined as HCV antibody positive and HCV RNA positive.
- CMV infection is defined as CMV DNA detectable.
- Syphilis infection is defined as syphilis antigen and antibody positive.
- HIV infection is defined as HIV 1/2 antibody positive.
- Other persistent or active infections requiring systemic treatment (prophylactic use of anti-infective drugs is allowed).
- Patients with central nervous system (CNS) diseases:
- Obvious risk or tendency of bleeding or active bleeding (eg, clinically significant hemoptysis, tumour bleeding, history of von Willebrand disease or hemophilia etc.).
- Plans to father a child during the study period.
- Patients with alcohol or drug abuse.
- Participants may not receive full-dose long acting oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose from the time of informed consent to 28 days post infusion of A-CAR032. Use of short acting direct oral anticoagulants for therapeutic and prophylactic purposes are permitted.
- Received the following:
- Major surgery within 4 weeks prior to apheresis or existence of unhealed wound, or planned major surgery within 4 weeks of the study treatment administration
- Steroids (except inhaled steroids) or other immunomodulators (including interleukins, interferons, and thymosins) of systemic therapeutic dose, and systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent within 5 half-lives or 7 days (whichever is shorter) prior to apheresis.
- Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy targeted therapy, biologic therapy, tumour embolisation, or monoclonal antibodies, investigational product) within 5 half-lives or ≤ 21 days (whichever is shorter) prior to apheresis.
- Radiotherapy within 4 weeks of apheresis (However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy); or within 6 months or 5 half-lives (whichever is longer) if local radioactive particle implantation was performed.
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China4 sites, 4 recruiting
- Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142
Xi-Nan Sheng, +86-10-88121122, xinan.sheng@bjcancer.org
- Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310013
Weijia Fang, +86-571-87236666, weijiafang@zju.edu.cn
- Not yet recruiting
Tongji Hospital, Tongji Medical College of HUST
Wuhan, Hubei, 430100
Bo Liu, +86-27-83663298, boliu888@hotmail.com
- Not yet recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221006
Zhengxiang Han, +86-516-85802000, cnhzxyq@163.com
About this study
Official title: First Time-in-Human (FTiH), Phase I Trial to Evaluate the Safety, Cellular Kinetics, and Efficacy of A-CAR032, in Adult Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with mCRPC, who have previously progressed after ARPI treatment of prostate cancer (whether before or in the metastatic castration-resistant setting) and, in the judgment of the investigator, are ineligible for standard treatment.
Read the detailed description
The study consists of two parts: Part 1-Dose Escalation and Part 2-Dose Expansion. Participants in the study will proceed through screening, apheresis, bridging therapy (if appropriate), lymphodepletion, CAR-T cell infusion, and subsequent follow-up (including Stage 1, 2 and 3).
- Being tested
- dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell InjectionBiological
dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection.single infusion intravenously.
| Study group | Role | What they receive |
|---|---|---|
| A-CAR032 | Experimental | Part 1 will follow an i3+3 design which is employed to explore the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE). Three dose levels of A-CAR032are initially planned with a minimum of 3 and maximum of 9 participants per dose level. The safety review committee (SRC) may suggest exploration of intermediate dose levels or additional higher or lower dose levels based on the available data, but will not exceed 3 times the current dose or 3 times the highest dose that has been determined safe by the SRC.Part 2 at the RDE of A-CAR032 will be initiated, if data support, to further evaluate the safety, CK, efficacy and potential biological activity of study intervention. Approximately 12 evaluable participants will be enrolled in Part 2. Receives: Biological: dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose Escalation (Part 1)：Safety
Incidence of AEs/SAEs
Measured: From ICF signature until 15 years post A-CAR032 infusion
Dose Escalation (Part 1)：Safety
Occurrence of DLTs/DLT-like events
Measured: Throughout the 28 days post A-CAR032 infusion
Dose Escalation (Part 1)：Safety
Changes from baseline in laboratory parameters, vital signs, and ECGs
Measured: From ICF signature until 12 months post A-CAR032 infusion
Dose Expansion (Part 2)：Safety
Incidence of AEs/SAEs
Measured: From ICF signature until 15 years post A-CAR032 infusion
Dose Expansion (Part 2)：Safety
Incidence of DLT-like events
Measured: Throughout the 28 days post A-CAR032 infusion
Dose Expansion (Part 2)：Safety
Changes from baseline in laboratory parameters, vital signs, and ECGs
Measured: From ICF signature until 12 months post A-CAR032 infusion
Secondary outcomes (6)
Dose Escalation (Part 1) and Dose Expansion (Part 2)：Efficacy
PSA-related response
Measured: From ICF signature until 12 months post A-CAR032 infusion
Dose Escalation (Part 1) and Dose Expansion (Part 2)：Efficacy
Radiological response
Measured: From ICF signature until 12 months post A-CAR032 infusion
Dose Escalation (Part 1) and Dose Expansion (Part 2)：Efficacy
rPFS
Measured: From ICF signature until 12 months post A-CAR032 infusion
Dose Escalation (Part 1) and Dose Expansion (Part 2)：Efficacy
OS
Measured: From ICF signature until 15 years post A-CAR032 infusion
Dose Escalation (Part 1) and Dose Expansion (Part 2)：Efficacy
Time from A-CAR032 infusion to first SSRE
Measured: From A-CAR032 infusion until 12 months post A-CAR032 infusion
Dose Escalation (Part 1) and Dose Expansion (Part 2)：Pharmacokinetics
CK profile of A-CAR032
Measured: From ICF signature until 15 years post A-CAR032 infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2026
- Study start13 Jan 2026
- Primary completion31 Jan 2027 (estimated)
- Study completion31 Jan 2042 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 27 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai AbelZeta Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07344311
- Sponsor's protocol ID
- 1332-046
- Status last verified
- Jan 2026
- First submitted
- 7 Jan 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No